drugset / Trial / NCT02517619

Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis

NCT02517619 ↗

Phase 3 Completed 251 enrolled Eyegate Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis.

Timeline

Start
2016-01-16
Primary completion
2018-04-20
Completion
2018-05-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 40 mg/ml Other
Comparator Prednisolone Other / unclassified 1 % Other

Indications